Unicycive Therapeutics, INC Schedule 13G passive stakes

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.3% of Unicivive Therapeutics Inc. common stock as of June 30, 2026.

Several entities affiliated with Millennium Management have reported a combined beneficial ownership of 1.8% of Unicycive Therapeutics' common stock as of June 30, 2026.

RA Capital Management and its affiliates filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Unicycive Therapeutics, Inc. as of March 31, 2026.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in UNICYCIVE THERAPEUTICS, INC. as of December 31, 2025.

Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, reported a combined 4.7% passive ownership stake in Unicycive Therapeutics, Inc. as of December 31, 2025.

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported beneficial ownership of 5.5% of Unicycive Therapeutics, Inc.'s common stock.

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, reported a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc.

Octagon Capital Advisors LP and affiliated entities, along with Ting Jia, reported a combined beneficial ownership of 5.7% of Unicycive Therapeutics, Inc.'s common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, disclosed a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc. as of September 30, 2025.

RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Unicycive Therapeutics, Inc., holding 1,960,230 shares of common stock as of September 30, 2025.

Great Point Partners, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, has reduced their beneficial ownership in Unicycive Therapeutics, Inc. to 4.51%.

Nantahala Capital Management and its managing members have reported an increased beneficial ownership of 9.99% in Unicycive Therapeutics, including shares from warrants.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 6.24% beneficial ownership stake in Unicycive Therapeutics, Inc.

Biotechnology Value Fund and its affiliates have increased their beneficial ownership in Unicycive Therapeutics, Inc. to 9.99% of outstanding common stock as of June 30, 2025.

Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, have disclosed a combined 7.8% beneficial ownership stake in Unicycive Therapeutics, Inc. through an amended Schedule 13G filing.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Unicycive Therapeutics, Inc., limited by a beneficial ownership blocker.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in UNICYCIVE THERAPEUTICS, INC., totaling 12,243,386 shares.

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a combined beneficial ownership of 9.99% of Unicycive Therapeutics, Inc.'s common stock as of March 31, 2025, including convertible preferred stock and warrants.

RA Capital Management, L.P. and its affiliated entities have filed an amended Schedule 13G, confirming their continued passive beneficial ownership of 9.9% in Unicycive Therapeutics, Inc. as of December 31, 2024.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have disclosed a combined beneficial ownership of 9.99% of Unicycive Therapeutics, Inc.'s common stock as of December 31, 2024.

Walleye Capital LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 4.82% of Unicycive Therapeutics, Inc.'s common stock as of December 31, 2024.